Small studies in patients with OSA and coexisting heart failure or type 2 diabetes have shown significant reductions in the AHI and improved nocturnal oxygen saturation with SGLT2 therapy [104]. This evidence concerns the gene SLC5A2 and obstructive sleep apnea syndrome.